Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Imugene Limited ( (AU:IMU) ) has provided an update.
Imugene Limited has announced the issuance of unquoted equity securities, including 95,653,854 restricted stock units and 3,570,072 performance rights awards, as part of an employee incentive scheme. This move is likely aimed at aligning employee interests with company goals and could impact the company’s operational dynamics and market positioning by potentially enhancing employee motivation and retention.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene Limited stock, see the AU:IMU Stock Forecast page.
More about Imugene Limited
Imugene Limited operates in the biotechnology industry, focusing on the development of immuno-oncology therapies. The company is primarily engaged in creating treatments that harness the immune system to fight cancer, aiming to provide innovative solutions in the oncology market.
Average Trading Volume: 23,361,624
Technical Sentiment Signal: Sell
Current Market Cap: A$141.9M
Find detailed analytics on IMU stock on TipRanks’ Stock Analysis page.